[go: up one dir, main page]

WO2007017892A3 - Novel compounds as glp-i agonists - Google Patents

Novel compounds as glp-i agonists Download PDF

Info

Publication number
WO2007017892A3
WO2007017892A3 PCT/IN2006/000154 IN2006000154W WO2007017892A3 WO 2007017892 A3 WO2007017892 A3 WO 2007017892A3 IN 2006000154 W IN2006000154 W IN 2006000154W WO 2007017892 A3 WO2007017892 A3 WO 2007017892A3
Authority
WO
WIPO (PCT)
Prior art keywords
glp
agonists
novel compounds
compounds
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2006/000154
Other languages
French (fr)
Other versions
WO2007017892A2 (en
Inventor
Braj Bhushan Lohray
Vidya Bhushan Lohray
Rajesh H Bahekar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002606894A priority Critical patent/CA2606894A1/en
Priority to BRPI0612471A priority patent/BRPI0612471A2/en
Priority to AP2007004227A priority patent/AP2007004227A0/en
Priority to MX2007013655A priority patent/MX2007013655A/en
Priority to JP2008509578A priority patent/JP2008540402A/en
Priority to AU2006277557A priority patent/AU2006277557A1/en
Priority to EA200702419A priority patent/EA200702419A1/en
Priority to EP06809915A priority patent/EP1891106A2/en
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of WO2007017892A2 publication Critical patent/WO2007017892A2/en
Publication of WO2007017892A3 publication Critical patent/WO2007017892A3/en
Priority to IL187105A priority patent/IL187105A0/en
Anticipated expiration legal-status Critical
Priority to NO20075618A priority patent/NO20075618L/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention describes a group of novel peptidomimetics useful for the treatment of diabetes. These compounds are defined by the general formula (I) as given below. A-X1- S1-Y-S2-X2-B (I)
PCT/IN2006/000154 2005-05-05 2006-05-04 Novel compounds as glp-i agonists Ceased WO2007017892A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EA200702419A EA200702419A1 (en) 2005-05-05 2006-05-04 NEW CONNECTIONS AS GLP-1 AGONISTS
AP2007004227A AP2007004227A0 (en) 2005-05-05 2006-05-04 Novel compounds as GLP-1 agonists
MX2007013655A MX2007013655A (en) 2005-05-05 2006-05-04 Novel compounds as glp-i agonists.
JP2008509578A JP2008540402A (en) 2005-05-05 2006-05-04 Novel compounds as GLP-1 agonists
AU2006277557A AU2006277557A1 (en) 2005-05-05 2006-05-04 Novel compounds as GPL-I agonists
CA002606894A CA2606894A1 (en) 2005-05-05 2006-05-04 Novel compounds as glp-i agonists
BRPI0612471A BRPI0612471A2 (en) 2005-05-05 2006-05-04 new compounds as glp-1 agonists
EP06809915A EP1891106A2 (en) 2005-05-05 2006-05-04 Novel compounds as glp-i agonists
IL187105A IL187105A0 (en) 2005-05-05 2007-11-01 Novel compunds as glp-i agonists
NO20075618A NO20075618L (en) 2005-05-05 2007-11-06 Novel compounds as GLP-1 Agonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN558/MUM/2005 2005-05-05
IN558MU2005 2005-05-05
IN645/MUM/2005 2005-05-31
IN645MU2005 2005-05-31

Publications (2)

Publication Number Publication Date
WO2007017892A2 WO2007017892A2 (en) 2007-02-15
WO2007017892A3 true WO2007017892A3 (en) 2007-09-20

Family

ID=37727716

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000154 Ceased WO2007017892A2 (en) 2005-05-05 2006-05-04 Novel compounds as glp-i agonists

Country Status (12)

Country Link
EP (1) EP1891106A2 (en)
JP (1) JP2008540402A (en)
KR (1) KR20080021636A (en)
AP (1) AP2007004227A0 (en)
AU (1) AU2006277557A1 (en)
BR (1) BRPI0612471A2 (en)
CA (1) CA2606894A1 (en)
EA (1) EA200702419A1 (en)
IL (1) IL187105A0 (en)
MX (1) MX2007013655A (en)
NO (1) NO20075618L (en)
WO (1) WO2007017892A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
EP2021014A1 (en) 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
WO2008062457A2 (en) * 2006-10-03 2008-05-29 Cadila Healthcare Limited Antidiabetic compounds
AU2008334783A1 (en) * 2007-12-11 2009-06-18 F. Hoffmann-La Roche Ag Insulinotropic peptide synthesis using solid and solution phase combination techniques
CA2707448C (en) * 2007-12-11 2014-10-14 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
SG175411A1 (en) * 2009-05-01 2011-12-29 Hoffmann La Roche Insulinotropic peptide synthesis using solid and solution phase combination techniques
CN101891823B (en) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 Exendin-4 and analog fusion protein thereof
EP2956160B1 (en) * 2013-02-15 2018-04-25 Mayo Foundation For Medical Education And Research Insulin secreting polypeptides

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO2002028438A1 (en) * 2000-10-05 2002-04-11 King's College London Lipopeptides as absorption enhancers for bioactive compounds
WO2003011892A2 (en) * 2001-07-31 2003-02-13 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1 exendin-4 peptide analogs and uses thereof
WO2003058203A2 (en) * 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
WO2004094461A2 (en) * 2003-04-21 2004-11-04 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
WO2005077072A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
WO2006014287A1 (en) * 2004-07-02 2006-02-09 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
WO2006024275A2 (en) * 2004-09-03 2006-03-09 Philipps-Universität Marburg Glp-1 and exendin related invention

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO2002028438A1 (en) * 2000-10-05 2002-04-11 King's College London Lipopeptides as absorption enhancers for bioactive compounds
WO2003011892A2 (en) * 2001-07-31 2003-02-13 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1 exendin-4 peptide analogs and uses thereof
WO2003058203A2 (en) * 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
WO2004094461A2 (en) * 2003-04-21 2004-11-04 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
WO2005077072A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
WO2006014287A1 (en) * 2004-07-02 2006-02-09 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
WO2006024275A2 (en) * 2004-09-03 2006-03-09 Philipps-Universität Marburg Glp-1 and exendin related invention

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AL-SABAH SULEIMAN ET AL: "A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 140, no. 2, September 2003 (2003-09-01), pages 339 - 346, XP002437826, ISSN: 0007-1188 *
CHAHRZAD MONTROSE-RAFIZADEH ET AL: "High Potency Antagonists of the Pancreatic Glucagon-like Peptide-1 Receptor", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 272, no. 34, 22 August 1997 (1997-08-22), pages 21201 - 21206, XP002247450, ISSN: 0021-9258 *
DOYLE MAIRE E ET AL: "The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity.", REGULATORY PEPTIDES, vol. 114, no. 2-3, 15 July 2003 (2003-07-15), pages 153 - 158, XP002441636, ISSN: 0167-0115 *
GREEN B D ET AL: "STRUCTURALLY MODIFIED ANALOGUES OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) AS FUTURE ANTIDIABETIC AGENTS", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, SCHIPHOL, NL, vol. 10, no. 29, 2004, pages 3651 - 3662, XP009068381, ISSN: 1381-6128 *
HINKE SIMON A ET AL: "In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 75, no. 15, 27 August 2004 (2004-08-27), pages 1857 - 1870, XP002387302, ISSN: 0024-3205 *
RUNGE S ET AL: "Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity.", BRITISH JOURNAL OF PHARMACOLOGY, vol. 138, no. 5, March 2003 (2003-03-01), pages 787 - 794, XP002427759, ISSN: 0007-1188 *
XIAO Q ET AL: "Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 40, no. 9, 6 March 2001 (2001-03-06), pages 2860 - 2869, XP002277645, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
BRPI0612471A2 (en) 2016-09-06
EA200702419A1 (en) 2008-04-28
NO20075618L (en) 2008-01-30
EP1891106A2 (en) 2008-02-27
IL187105A0 (en) 2008-02-09
JP2008540402A (en) 2008-11-20
MX2007013655A (en) 2008-01-24
AP2007004227A0 (en) 2007-12-31
WO2007017892A2 (en) 2007-02-15
KR20080021636A (en) 2008-03-07
CA2606894A1 (en) 2007-02-15
AU2006277557A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
WO2007085895A3 (en) Fap inhibitors
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
CR9369A (en) ACETIC ACID PERIDIL COMPOUNDS
WO2009030469A8 (en) Fungicidal 2-alkylthio-2-quinolinyloxy-acetamide deritvatives
EP2677562A3 (en) Arylamines for organic electroluminescent devices
WO2009156462A3 (en) Organic compounds
WO2009043889A3 (en) Oxadiazole derivatives
WO2009146218A3 (en) Compounds including an anti-inflammatory pharmacore and methods of use
WO2007003962A3 (en) Gpcr agonists
WO2009079008A8 (en) Benzopyrans and analogs as rho kinase inhibitors
WO2007003961A3 (en) Gpcr agonists
WO2006092213A8 (en) Pyrazolylcarboxanilides
WO2008001931A3 (en) Fused cyclic compounds
CR9866A (en) NOVEDOSOS DERIVED FROM 1-AZA-BICICLOALQUILO FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENERATIVE DISORDERS
WO2009019015A8 (en) Novel herbicides
WO2009049716A8 (en) Novel fungicides
WO2008059370A8 (en) Substituted bicyclocarboxyamide compounds
MX2010004669A (en) Preparation of dihydropyrrol derivatives as intermediates.
MX2009008660A (en) Method for the preparation of therapeutically valuable triphenylbutene derivatives.
WO2009121939A3 (en) C-aryl glycoside compounds for the treatment of diabetes and obesity
MX2007014172A (en) Processes for production of phenolic 4-biphenylylazetidin-2-ones.
WO2008151828A8 (en) Novel microbiocides
WO2009000533A8 (en) Novel herbicides
MX2009004991A (en) Cyclopentene diol monoacetate derivatives.
NO20075618L (en) Novel compounds as GLP-1 Agonists

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/013655

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 187105

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008509578

Country of ref document: JP

Ref document number: 12007502447

Country of ref document: PH

Ref document number: 2606894

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006809915

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006277557

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 07121830

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2006277557

Country of ref document: AU

Date of ref document: 20060504

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006277557

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077028300

Country of ref document: KR

Ref document number: 200702419

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 564030

Country of ref document: NZ

Ref document number: 1200702605

Country of ref document: VN

WWW Wipo information: withdrawn in national office

Ref document number: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06809915

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 200680024277.1

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006809915

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0612471

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20071105